Clinical TrialsAmadeo2025-01-31T10:29:05+00:00 Clinical Trials Clinico-immunological efficacy of Streptococcus salivarius K12 in the prevention of exacerbations and treatment of chronic tonsillitis in children. Marushko et al.2018 Modern possibilities of prevention of recurrent infections of the pharynx in children when using antibiotics. Gavrilenko.2018 Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. Di Pierro et al.2018 Possibilities of using lantibiotics in the prevention of recurrent or upper respiratory tract infections in children. Kryuchko and Tkachenko.2017 Clinical evaluation of the therapeutic use of oral probiotic streptococcus salivarius K12 for recurrent pharyngitis and/or tonsillitis. Gun.2017 Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Di Pierro et al.2016 Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Di Pierro et al.2016 Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Gregori et al.2016 Oral use of Streptococcus salivarius K12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study. Di Pierro et al.2015 Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Di Pierro et al.2014 « Previous Page1 Page2 Page3 Page4 Next » Year All 2004 2005 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 All 2004 2005 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Health Area Respiratory health Respiratory health
Clinico-immunological efficacy of Streptococcus salivarius K12 in the prevention of exacerbations and treatment of chronic tonsillitis in children. Marushko et al.2018
Modern possibilities of prevention of recurrent infections of the pharynx in children when using antibiotics. Gavrilenko.2018
Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. Di Pierro et al.2018
Possibilities of using lantibiotics in the prevention of recurrent or upper respiratory tract infections in children. Kryuchko and Tkachenko.2017
Clinical evaluation of the therapeutic use of oral probiotic streptococcus salivarius K12 for recurrent pharyngitis and/or tonsillitis. Gun.2017
Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Di Pierro et al.2016
Positive clinical outcomes derived from using Streptococcus salivarius K12 to prevent streptococcal pharyngotonsillitis in children: a pilot investigation. Di Pierro et al.2016
Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Gregori et al.2016
Oral use of Streptococcus salivarius K12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study. Di Pierro et al.2015
Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Di Pierro et al.2014
